PL391884A1 - Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania stanom zapalnym naczyń - Google Patents

Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania stanom zapalnym naczyń

Info

Publication number
PL391884A1
PL391884A1 PL39188402A PL39188402A PL391884A1 PL 391884 A1 PL391884 A1 PL 391884A1 PL 39188402 A PL39188402 A PL 39188402A PL 39188402 A PL39188402 A PL 39188402A PL 391884 A1 PL391884 A1 PL 391884A1
Authority
PL
Poland
Prior art keywords
pro
prevention
treatment
derivatives
interleukin
Prior art date
Application number
PL39188402A
Other languages
English (en)
Other versions
PL223229B1 (pl
Inventor
Thomas Lauger
Original Assignee
Luger Thomas
Grabbe Stephan
Brzoska Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luger Thomas, Grabbe Stephan, Brzoska Thomas filed Critical Luger Thomas
Publication of PL391884A1 publication Critical patent/PL391884A1/pl
Publication of PL223229B1 publication Critical patent/PL223229B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/85—Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C12N2501/86—Melanocyte-stimulating hormone [MSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL391884A 2001-02-14 2002-02-08 Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania stanom zapalnym naczyń PL223229B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10106852A DE10106852A1 (de) 2001-02-14 2001-02-14 Entzündungshemmende Verbindungen

Publications (2)

Publication Number Publication Date
PL391884A1 true PL391884A1 (pl) 2010-09-13
PL223229B1 PL223229B1 (pl) 2016-10-31

Family

ID=7674019

Family Applications (3)

Application Number Title Priority Date Filing Date
PL369526A PL221492B1 (pl) 2001-02-14 2002-02-08 Zastosowanie dipeptydu lub tripeptydu do wytwarzania leków hamujących zapalenie
PL391988A PL223478B1 (pl) 2001-02-14 2002-02-08 Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania odpowiedzi immunologicznej na tle zapalnym
PL391884A PL223229B1 (pl) 2001-02-14 2002-02-08 Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania stanom zapalnym naczyń

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL369526A PL221492B1 (pl) 2001-02-14 2002-02-08 Zastosowanie dipeptydu lub tripeptydu do wytwarzania leków hamujących zapalenie
PL391988A PL223478B1 (pl) 2001-02-14 2002-02-08 Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania odpowiedzi immunologicznej na tle zapalnym

Country Status (17)

Country Link
US (4) US8003608B2 (pl)
EP (6) EP2189156A1 (pl)
JP (1) JP4259870B2 (pl)
CN (3) CN101215544B (pl)
AT (2) ATE358475T1 (pl)
AU (2) AU2002253000B2 (pl)
CA (1) CA2437788C (pl)
CY (4) CY1106563T1 (pl)
DE (3) DE10106852A1 (pl)
DK (4) DK2198723T3 (pl)
ES (4) ES2361422T3 (pl)
MX (1) MXPA03007255A (pl)
NZ (2) NZ542406A (pl)
PL (3) PL221492B1 (pl)
PT (4) PT2198723E (pl)
SI (4) SI1749524T1 (pl)
WO (1) WO2002064131A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
DE60206037T2 (de) * 2001-05-25 2006-07-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Lektin-ähnliche domäne von thrombomodulin und therapeutische verwendung davon
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
WO2006009325A1 (ja) * 2004-07-23 2006-01-26 Ono Pharmaceutical Co., Ltd. メタロプロテアーゼ阻害剤
EP1813271A4 (en) * 2004-10-26 2008-05-21 Ajinomoto Kk PREVENTIVE / THERAPEUTIC AGENT FOR VISCERAL PAIN
WO2007004613A1 (ja) * 2005-07-01 2007-01-11 Ajinomoto Co., Inc. 炎症性腸疾患治療薬及びＴＮＦ－α産生抑制剤
EP1782819A1 (en) * 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
DE102006003854A1 (de) * 2006-01-26 2007-08-02 Universität Duisburg-Essen Regulatorische und cytotoxische CD8+ T-Zellen
WO2009065857A2 (en) * 2007-11-19 2009-05-28 Universitätsklinikum Münster Compositions for reducing oxidative stress and uses thereof
CA2845183A1 (en) 2011-09-23 2013-03-28 Westfaelische Wilhelms-Universitaet Muenster Tripeptide kdpt for antiapoptotic treatment
MX2014011290A (es) 2012-03-20 2014-10-13 Helix Biomedix Inc Lipopeptidos antimicrobianos cortos.
BR112015027569A2 (pt) * 2013-05-10 2017-09-19 Southern Res Inst compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß
BR112016006348A2 (pt) 2013-09-23 2020-05-19 Dr. August Wolff Gmbh & Co. Kg Arzneimittel tripeptídeos anti-inflamatórios
TR201902755T4 (tr) 2013-11-07 2019-03-21 Dr August Wolff Gmbh & Co Kg Arzneimittel Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari.
CN107349416A (zh) * 2017-08-01 2017-11-17 中山大学 一种含三肽化合物的抗骨关节炎药物
CN117777239A (zh) * 2017-09-15 2024-03-29 凯恩塞恩斯株式会社 作为自身免疫疾病及骨病治疗剂的肽的用途
CN111150831B (zh) * 2020-02-27 2023-06-09 广州领晟医疗科技有限公司 多肽KdPT的应用
US11793746B2 (en) * 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
CN114432421B (zh) * 2022-01-12 2024-04-12 广州领晟医疗科技有限公司 一种用于治疗急性肺损伤的KdPT多肽及其应用
CN114404562A (zh) * 2022-01-17 2022-04-29 广州领晟医疗科技有限公司 一种用于治疗骨关节炎的KdPT多肽及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3778550D1 (de) 1986-08-08 1992-05-27 Univ Texas Fieber- und entzuendungshemmende peptide.
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
IL89770A (en) 1988-03-28 1994-12-29 British Tech Group Analgesic peptides and pharmaceutical compositions containing them and the process for the preparation of some such compounds
ES2012532A6 (es) * 1988-07-15 1990-04-01 Cusi Lab Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica.
DE3844046A1 (de) * 1988-12-28 1990-07-05 Hoerrmann Wilhelm Arzneimittel, die isomere des hydroxylysins oder lysins enthalten
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
WO1992009279A1 (fr) * 1990-11-30 1992-06-11 Teijin Limited Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
SK91395A3 (en) * 1993-01-22 1996-12-04 Pfizer Lysine salt of 6-chloro-5-fluoro-3-(2-tenoyl)-2-oxindole-1- -carboxamide and pharmaceutical composition on their base
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) * 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
SE9500270L (sv) * 1995-01-25 1996-09-09 A K J Medi Konsult Ab Läkemedel mot bristtillstånd
CA2212127A1 (en) * 1995-02-03 1996-08-08 Cosmederm Technologies Formulations and methods for reducing skin irritation
FR2733421B1 (fr) 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
JP3567350B2 (ja) * 1996-03-13 2004-09-22 株式会社ホーネンコーポレーション 抗脱毛症剤
JP3922594B2 (ja) 1996-03-19 2007-05-30 株式会社ノエビア 抗菌性低刺激化粧料
AU3224997A (en) * 1996-05-29 1998-01-05 Prototek, Inc Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
DE69738907D1 (de) * 1996-10-11 2008-09-25 Kowa Co Neue diamidverbindungen und medikamente die diese enthalten
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
SE9801571D0 (sv) * 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
FR2784028B1 (fr) * 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
JP3962166B2 (ja) * 1998-10-19 2007-08-22 株式会社資生堂 皮膚外用剤
WO2000037071A1 (en) * 1998-12-21 2000-06-29 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
ATE332963T1 (de) * 1999-01-22 2006-08-15 Schepens Eye Res Inst Aktivierung von regulatorischen t zellen durch ein alpha-melanocyten stimulierendes hormon
WO2000054750A1 (fr) * 1999-03-15 2000-09-21 Dmitry Anatolievich Starchenko Procede de correction des perturbations dans la synthese du collagene et substance bioactive de mise en oeuvre de ce procede
JP2004506417A (ja) * 2000-07-14 2004-03-04 ザイコス　インク． α−ＭＳＨ関連化合物および使用方法
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
US7960508B2 (en) 2001-05-11 2011-06-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Peptide having cytotoxicity inhibitory activity and method of screening these peptide having cytotoxicity inhibitory activity

Also Published As

Publication number Publication date
CY1106563T1 (el) 2012-01-25
CA2437788C (en) 2011-04-05
US20040077552A1 (en) 2004-04-22
AU2002253000B2 (en) 2006-05-25
PT2198723E (pt) 2013-06-12
US8003608B2 (en) 2011-08-23
US20120045462A1 (en) 2012-02-23
CN101215544A (zh) 2008-07-09
US20170087202A1 (en) 2017-03-30
PL223478B1 (pl) 2016-10-31
US8846617B2 (en) 2014-09-30
US10046020B2 (en) 2018-08-14
PT2196202E (pt) 2013-09-24
ES2361422T3 (es) 2011-06-16
WO2002064131A2 (de) 2002-08-22
ES2281511T3 (es) 2007-10-01
DK2198723T3 (da) 2013-06-17
CN101215544B (zh) 2011-05-04
SI2196202T1 (sl) 2013-09-30
NZ528191A (en) 2005-11-25
EP1427405B1 (de) 2007-04-04
PL221492B1 (pl) 2016-04-29
CY1111450T1 (el) 2015-08-05
US20150087578A1 (en) 2015-03-26
ES2427970T3 (es) 2013-11-05
US9550807B2 (en) 2017-01-24
HK1140960A1 (en) 2010-10-29
EP2198723A1 (de) 2010-06-23
EP2260843A2 (de) 2010-12-15
DK1749524T3 (da) 2011-06-06
CN101810847B (zh) 2013-02-13
PL369526A1 (pl) 2005-05-02
CN1541095A (zh) 2004-10-27
EP1749524A3 (de) 2007-11-28
AU2006203622B2 (en) 2007-08-09
DK2196202T3 (da) 2013-09-08
WO2002064131A3 (de) 2004-04-01
NZ542406A (en) 2007-04-27
EP2196202B1 (de) 2013-07-17
EP1427405A2 (de) 2004-06-16
PL391988A1 (pl) 2010-09-13
EP2260843A3 (de) 2011-08-03
CA2437788A1 (en) 2002-08-22
CY1114024T1 (el) 2016-07-27
PT1427405E (pt) 2007-05-31
DE50214981D1 (de) 2011-05-05
SI1749524T1 (sl) 2011-08-31
PL223229B1 (pl) 2016-10-31
CN101810847A (zh) 2010-08-25
HK1061980A1 (en) 2004-12-10
EP1749524B1 (de) 2011-03-23
MXPA03007255A (es) 2005-02-14
ATE358475T1 (de) 2007-04-15
DK1427405T3 (da) 2007-07-02
DE10106852A1 (de) 2002-09-05
DE50209873D1 (de) 2007-05-16
HK1095538A1 (en) 2007-05-11
EP2196202A1 (de) 2010-06-16
ATE502632T1 (de) 2011-04-15
HK1140915A1 (zh) 2010-10-29
PT1749524E (pt) 2011-05-25
JP4259870B2 (ja) 2009-04-30
SI1427405T1 (sl) 2007-08-31
EP1749524A2 (de) 2007-02-07
AU2006203622A1 (en) 2006-09-07
EP2189156A1 (de) 2010-05-26
SI2198723T1 (sl) 2013-06-28
CY1114214T1 (el) 2016-08-31
ES2411935T3 (es) 2013-07-09
JP2004533995A (ja) 2004-11-11
EP2198723B1 (de) 2013-04-10
CN1269477C (zh) 2006-08-16

Similar Documents

Publication Publication Date Title
PL391884A1 (pl) Zastosowanie związku do wytwarzania leku do leczenia i/lub zapobiegania stanom zapalnym naczyń
Guzman-Marin et al. Rapid eye movement sleep deprivation contributes to reduction of neurogenesis in the hippocampal dentate gyrus of the adult rat
Mendelson et al. Effects of melatonin and propranolol on sleep of the rat
Gonzalez et al. Chronic photodamage in skin of mast cell‐deficient mice
CY1111265T1 (el) Χρηση πεπτιδικων παραγωγων για διεγερση διαφοροποιησης κυτταρου
JPH10513149A (ja) キナゾリノン医薬品及びその利用
AR042103A1 (es) Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion
CN1154484C (zh) 司来吉兰或去甲基司吉兰在生产治疗创伤、烧伤、光照损害的药物中的用途
EP1392346A2 (en) Composition and method for enhancing elasticity of tissue
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
KR100883342B1 (ko) 글루타민을 함유한 아토피 피부염 치료용 약제학적 조성물
CA2501738A1 (en) Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin
WO2001070236A8 (en) Preventing and/or treating diabetes mellitus
ATE374781T1 (de) Derivate von genkwanin und sakuranetin, deren kosmetische und therapeutische verwendung, und verfahren zu deren herstellung
Malo et al. Inhibition by auranofin of pharmacologic and antigen-induced contractions of the isolated guinea pig trachea
US4689213A (en) Method and composition for treating bronchospastic airway diseases
KR101162389B1 (ko) 손상된 결합조직 억제용 오르가노-실리콘의 용도
WO1999000079A1 (en) Skin aging and wound treatment using cell migration agents
RU99108220A (ru) Способ лечения острого периода гипоталамического синдрома пубертатного периода
JP2004083434A (ja) コラーゲン合成促進剤
Nakamoto et al. Effect of allergen immunotherapy on nasal responses in guinea‐pigs with allergic rhinitis
Lepistö et al. Stimulation of wound healing by the immunomodulator LS-2616 (Linomide)
Tanaka et al. Evaluation of an antiallergic agent (disodium cromoglycate) in rat conjunctiva using monoclonal IgE antibody
ITBO950465A1 (it) Modo di assunzione di vitamina c e mono-disaccaridi in pozione per uso umano, normalizzatrice dei ph intestinale e sanguigno alterati da
Chan et al. Early release of mitochondrial cytochrome c and the subsequent activation of caspase-3 are involved in the apoptotic death of neonatal motoneurons after injury